Abstract: The present invention relates to an ophthalmic solution comprising 0.00001 to 10.0 weight percent of a simple saccharide, at least 0.00001 weight percent of a preservative, and not more than about 0.2 percent by weight chloride. The simple saccharide is chosen from the group consisting of: inositol; mannitol; sorbitol; sucrose; dextrose; glycerin; propylene glycol; ribose; triose; tetrose; erythrose; threose; pentose; arabinose; ribulose; xylose; xylulose; lyxose; hexose; allose; altrose; fructose; galactose; glucose; gulose; idose; mannose; sorbose; talose; tagatose; adlose; ketose; heptose; sedoheptulose; monosaccharides; disaccharides; sugar alcohols; xylitol; and polyol.
Abstract: An immunomodulator useful for modulating immune function and maintaining intravital homeostasis is provided. The immunomodulator comprises S-1-propenycysteine or a salt thereof as an active ingredient.
Abstract: There is provided a composition for treating a neuroinflammatory disease comprising a N-carbamoylated urethane compound which has an effect of inhibiting the activity of microglia or astrocytes and the production of nitric oxide (NO) and TNF-?, and suppressing the expression of IL-1? And iNOS genes. There is also provide a method for treating a neuroinflammatory disease, the method comprising the step of administering a N-carbamoylated urethane compound. Due to its above mentioned effects, the N-carbamoylated urethane compound according to the present invention can be useful for the treatment of neuroinflammatory diseases.
Type:
Grant
Filed:
April 24, 2017
Date of Patent:
March 26, 2019
Assignee:
Kyungpook National University Industry-Academic Cooperation Foundation
Inventors:
Kyoungho Suk, Gyun Jee Song, Youngpyo Nam, Myungjin Jo
Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.
Type:
Grant
Filed:
February 27, 2017
Date of Patent:
March 12, 2019
Assignees:
HOFFMANN-LA ROCHE INC., EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRCIH, UNIVERSITÄT ZÜRICH
Inventors:
Simon M. Ametamey, Juergen Fingerle, Luca Gobbi, Uwe Grether, Ahmed Haider, Thomas Hartung, Linjing Mu, Leo Nicholls, Mark Rogers-Evans, Christoph Ullmer
Abstract: Uses of melanin and its derivatives, analogs, and precursors for the treatment and prevention of ocular diseases, disorders, and conditions, are described. Melanin, or a derivative, analog, or precursor thereof, such as synthetic melanin or natural melanin, is applied to the eye by topical application or injection. Examples of ocular diseases, disorders, and conditions that can be treated or prevented by the methods described herein include hyperemia, leukoplakia, corneal angiogenesis, and corneal keratoconus.
Abstract: The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophthalmological diseases in humans and animals.
Abstract: The present invention is directed to preservative-free solutions of brimonidine and timolol for lowering intra-ocular pressure and treatment of glaucoma.
Type:
Grant
Filed:
July 28, 2011
Date of Patent:
February 26, 2019
Assignee:
Allergan, Inc.
Inventors:
Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly
Abstract: The invention provides novel substituted amino triazoles of Formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, as well as pharmaceutical compositions comprising the same. The compounds of the invention are inhibitors of acidic mammalian chitinase (AMCase) and are useful, in a non-limiting embodiment, for treating asthma. The invention further provides methods of using compounds and/or compositions of the invention to treat asthma and/or to monitor asthma treatment.
Type:
Grant
Filed:
December 19, 2014
Date of Patent:
February 26, 2019
Assignee:
Institute for Drug Discovery, LLC
Inventors:
Michael L. Corman, William M. Hungerford, Adam Golebiowski, Raymond P. Beckett, Marzena Mazur, Sylwia Olejniczak, Jacek Olczak
Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.
Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
Type:
Grant
Filed:
February 13, 2018
Date of Patent:
February 12, 2019
Assignee:
SYDNEXIS, INC.
Inventors:
Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
Abstract: A ferumoxytol-based dual-modality imaging probe for long-term stem cell tracking through MRI and early diagnosis of cell apoptosis through simultaneous fluorescence imaging is provided. Specifically, a ferumoxytol-based dual-modality imaging probe is provided with enhanced T2* relaxivity for tracking stem cells through magnetic resonance imaging and detecting apoptotic stem cells through fluorescence imaging.
Type:
Grant
Filed:
August 4, 2017
Date of Patent:
January 29, 2019
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Kai Li, Heike E. Daldrup-Link, Hossein Nejadnik
Abstract: Provided are a sustained release pheromone preparation capable of maintaining a high amount of pheromone release throughout a control period of vine mealybug (VMB) having lavandulyl senecioate (LVSN) as a pheromone substance; and a control method with the preparation. More specifically, provided are a sustained release pheromone preparation comprising a first pheromone substance, and a first container having the first pheromone substance sealed therein and comprising a first polymer membrane made of an ethylene vinyl acetate copolymer containing vinyl acetate units of from 0.5 to 10% by weight, wherein the first pheromone substance is lavandulyl senecioate, which is a pheromone substance of vine mealybug, and the lavandulyl senecioate can be released into the air through the first polymer membrane for 150 days or more; and others.
Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
January 22, 2019
Inventors:
David P. Bingaman, Paul G. Chaney, Martin B. Wax
Abstract: The present invention relates to a pharmaceutical composition comprising (a) 7?-hydroxycholesterol, (b) a water soluble organic solvent, preferably propylene glycol and/or DMSO, and (c) a solubilizing agent, preferably PEG hydrated castor oil, and to a method for preparing the same. This composition is suitable for preparing an intravenously administered preparation and comprises the pharmaceutically active substance ?-hydroxycholesterol, which is poorly soluble in water.
Type:
Grant
Filed:
January 12, 2017
Date of Patent:
January 15, 2019
Assignee:
IMMUNOPHARM AG
Inventors:
Werner Bieberschulte, Christine Grimm, Rohan Charles Fernando
Abstract: Disclosed are pharmaceutical compositions comprising mdivi-1 and nutlin-3, individually and in combination, for topical or intravitreal ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma, optic neuropathies including Leber Hereditary Optic Neuropathy, arteritic or non-arteritic Ischemic Optic Neuropathy, and retinal artery and vein occlusions.
Abstract: The present invention relates to a lens care solution having 0.001 to about 5 weight percent of a low molecular weight amine of the general formula: where R1, R2, R3 and R4 are —H or low molecular weight radicals, and R5 is a low molecular weight radical, or salt thereof; an effective amount of a tonicity agent; and the balance water.
Abstract: Methods and apparatus for inducing weight loss using blood flow control are described herein. The apparatus and methods operate by controlling blood flow to the stomach and/or small bowel.
Type:
Grant
Filed:
March 5, 2015
Date of Patent:
November 13, 2018
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Gianrico Farrugia, Paul A. Friedman, Elizabeth Rajan, Charles J. Bruce, Samuel J. Asirvatham, Michael J. Levy, Louis-Michel Wong Kee Song, Juliane Bingener-Casey, Navtej S. Buttar
Abstract: The embodiments herein disclose a method of fabricating composite scaffolds for skin tissue regeneration. The methacrylated hyaluronic acid (HAMA) and methacrylated gelatin (GelMA) are synthesized. The poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds are synthesized. The hydrogel is synthesized. The composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds is fabricated. A plurality of physico-chemical characteristics of the composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds are analysed. The physico-chemical characteristics comprises mechanical properties, swelling ratio and enzymatic degradation and scanning electron microscope imaging. The fibroblast cells are encapsulated within the composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(?-caprolactone) (PGS-PCL) microfibrous scaffolds and hydrogels.